tein (TSG) (also referred to as SP-], PAPP-C, PSBG or PSbG) was first identified immunochemically in the serum of pregnant women and placental tissue (Tatarinov & Masyukevich, 1970;  Bohn, 1971; Lin et al., 1974) . Subsequently, TSG was discovered in the serum of patients with trophoblastic (Tatarinov et al., 1974) and testicular tumours (Tatarinov et al., 1975; Johnson et al., 1977) and in non-trophoblastic malignancies (Horne et al., 1976; Tatarinov & Sokolov, 1977) and the frequency of raised levels of TSG was compared with HCCG in these tumour groups Seppala et al., 1978; Searle et al., 1978; Tatarinov et al., 1976; Johnson et al., 1977; Wuirz et al., 1979) .
This study will present our recent data on the clinical application of TSG assays in patients with trophoblast and nontrophoblast tumours.
Sera radioimmunoassay as described previously (Tatarinov & Sokolov, 1977) . The sensitivity of the double-antibody radioimmunoassay for TSG was -1 ng/ml; the lowest measurable serum level of TSG was 3 ng/ml. Monospecific antisera to TSG (anti-TSG) were prepared in rabbits as described previously (Tatarinov & Masyukevich, 1970) . Donkey anti-rabbit y-globulin (anti-RGG) was purified from commercial antisera prepared at the Gamaleya Institute of Epidemiology and Microbiology, Moscow, U.S.S.R.
TSG was isolated from pooled pregnancy sera by a combination of methods already described (Bohn, 1971; Lin et al., 1974) . The protein fraction prepared by chromatography with KM-32 cellulose was purified further by isoelectrofocusing. The resulting fraction (pl 4.05) was used to prepare 1251-labelled TSG. Its purity was controlled immunologically by disc electrophoresis, using as comparison a sample of pregnancy-specific 3i-glycoprotein (SP-1; Bohn, 1971) provided by Dr Sizaret (International Agency for Research on Cancer, Lyon, France).
TSG was labelled with 1251 (Tatarinov & Sokolov, 1977) . 041 ml of 01M phosphate-buffered saline (PBS, pH 7-6) containing 30 Hug of TSG was added to 0-1 ml of PBS containing 041 mg of chloramine-T and 2 mCi carrier-free Na1 251 with a specific activity of 106 mCi/ml (Leningrad, I)epartment of 13iocliemistry, 2nd i\Ioscowr MIedical tubes were incubated at 4°C for 24 h in a Rotamixer. After incubation and measurement of the total amount of radioactivity in each sample, 0-1 ml of anti-RGG diluted 1:5 in PBS was added. The anti-TSG-bound TSG was precipitated by anti-RGG. The tubes were incubated at 20°C for 4 h in a Rotamixer and centrifuged at 2000 g for 20 min. The supernatant was removed by suction. The precipitate was resuspended in 1 ml of PBS and recentrifuged in the same manner. After removal of the supernatant, the radioactivity of the tubes was assessed. Nonspecific radioactivity in control tubes was about 1-1.500. An antibody concentration (1:32,000), precipitating 5000 of the 1251-TSG, was used for the subsequent construction of inhibition curves. The standard inhibition curve was constructed by diluting 0, 0.5, 1.0, 1.5, 3*0, 6-0, 12-0, 24-0, 48-0, 96-0, 192-0 and 384-0 ng per ml of a weighed amount of purified TSG and of known immunodiffusion TSG-positive sera in 0415 ml of PBS containing 5% BSA. For the assay, reagents were addied in the following order: (1) 0.15 ml anti-TSG appropriately diluted: e.g. 1:32,000; (2) 0 05 ml 1251-TSG dilution containing 32,000 ct/min; (3) 0*05 ml of test serum sample or standard TSG; (4) After 16 h of incubation at 20°C, 041 ml of immunoadsorbant containing anti-RGG was added and left to stand for 4 h in the The methods of immunoelectrophoresis in agar, disc-electrophoresis, double immunodiffusion in agar with standard test system and immunoradioautography for identification and titration of TSG, have been reported in previous publications (Tatarinov & Masyukevich, 1970; Tatarinov & Sokolov, 1977) .
The circulating levels of TSG in healthy non-pregnant female and male donors fall below 10 ng/ml in almost all cases, and in 58% were less than 3 ng/ml. Only 30o had levels between 10 and 11 ng/ml. A cut-off point of 10 ng/ml was therefore selected to mark the upper limit of normal.
Elevated serum TSG levels in the range 10,000-320,000 ng/ml were demonstrated in all 15 patients with hydatidiform moles.
TSG concentrations in these patients were similar to those found in women during a normal pregnancy. Raised serum TSG levels were recorded in 7500 of patients with post-molar trophoblast tumours, and in 67% of patients with uterine choriocarcinomas (Table I) . Circulating TSG levels before the start of therapy ranged from 50 to 16,000 ng/ml in most patients. The incidence of pathological levels in sera from patients with trophoblast tumours in different countries is similar (Table II) . Tables I and III show the occurrence of elevated TSG levels in a variety of nontrophoblast tumours. In 8% of cases with non-trophoblast tumours, the circulating TSG level was raised, but levels higher 56 than 100 ng/ml were rare (Tables I and  III) . The detection of TSG in the sera of 7000 of patients with gestational trophoblast tumours, including uterine choriocarcinomas, suggests that this immunochemical test for TSG may have diagnostic value. The correlation of TSG and human chorionic gonadotrophin (hCG) release by gestational trophoblast tumours has been discussed by a number of authors (Tatarinov et al., 1976; Bagshawe et al., 1978; Searle et al., 1978; Seppala et al., 1978; Than et al., 1979) . From these data it would be reasonable to assume that TSG assays may play an ancillary role to hCG assays for such lesions. However, assays for TSG alone have an important role in epidemiological investigations, particularly in population groups with a high risk of trophoblast disease (Tatarinov et al., 1976) . The relationship of high serum TSG levels to the function of the various histological subtypes of both choriocarcinomas (Tatarinov et al., 1976; Zavadil, 1974) and teratomas is now under active study.
High TSG levels in non-trophoblastic tumours, particularly in breast and lung carcinomas, might have an ectopic origin. Our results agree with recent data concerning the finding of TSG in non-trophoblast tumours with or without the chorion elements Johnson et al., 1977; Wurz et al., 1979) . TSG could be a product of an activated placental gene in malignant tissues, although this seems to occur only in a very low percentage of non-trophoblast tumours.
In conclusion, the present test for TSG has proved to be highly specific for trophoblast tumours, and may be used in its differential diagnosis and possibly also in epidemiological studies of post-molar trophoblast disease.
